Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $381K | $505K | $378K | $245K | $366K | $359K | $386K | $488K | $683K | $593K |
| Revenue growth | — | 32.6% | -25.1% | -35.3% | 49.6% | -1.9% | 7.5% | 26.4% | 40.0% | -13.2% |
| Operating income | -$40.1M | -$25.6M | -$17.1M | -$16.7M | -$19.1M | -$28.9M | -$39.9M | -$45.4M | -$48.7M | -$49.0M |
| Operating margin | -10534.9% | -5064.4% | -4507.6% | -6817.8% | -5214.8% | -8037.6% | -10337.3% | -9305.7% | -7123.1% | -8256.3% |
| Net income | -$39.2M | -$24.9M | -$16.5M | -$16.4M | -$19.3M | -$28.3M | -$38.7M | -$41.4M | -$45.4M | -$45.9M |
| Net margin | -10287.7% | -4928.1% | -4351.1% | -6709.7% | -5275.1% | -7880.5% | -10026.9% | -8492.0% | -6651.7% | -7732.0% |
| EPS (diluted) | -$1.37 | -$51.76 | -$8.26 | -$2.80 | -$1.08 | -$0.73 | -$0.89 | -$0.93 | -$0.95 | -$0.69 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$31.0M | -$23.3M | -$13.2M | -$13.3M | -$16.3M | -$23.0M | -$33.8M | -$30.9M | -$37.7M | -$37.9M |
| Capital expenditures | $823K | $101K | $5.10K | $67.6K | $211K | $205K | $1.01M | $582K | $80.0K | $44.0K |
| Free cash flow | -$31.9M | -$23.4M | -$13.2M | -$13.3M | -$16.5M | -$23.2M | -$34.8M | -$31.5M | -$37.8M | -$38.0M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $13.9M | $8.23M | $11.5M | $10.2M | $131M | $11.9M | $16.3M | $21.7M | $51.5M | $17.5M |
| Total assets | $44.0M | $12.3M | $14.2M | $13.1M | $135M | $150M | $116M | $81.6M | $97.2M | $61.9M |
| Total liabilities | $24.2M | $5.78M | $4.09M | $5.78M | $6.57M | $9.13M | $9.85M | $11.9M | $14.2M | $16.5M |
| Shareholders' equity | $19.8M | $6.51M | $10.1M | $7.31M | $128M | $140M | $106M | $69.7M | $82.9M | $45.4M |
| Retained earnings | -$148M | -$173M | -$192M | -$209M | -$231M | -$260M | -$298M | -$340M | -$384M | -$430M |
| Shares (wtd avg diluted) | 30.3M | 482K | 2.33M | 5.97M | 20.9M | 39.0M | 43.6M | 44.7M | 47.6M | 66.8M |
Every figure is extracted from Cardiff Oncology, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.